Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

Details for Australian Patent Application No. 2006254902 (hide)

Owner President and Fellows of Harvard Col- lege Emory University The Brigham and Women's Hospital, Inc. DanaFarber Cancer Institute

Inventors Dorfman, David M.; Wherry, E. John; Ahmed, Rafi; Freemon, Gordon; Barber, Daniel; Sharpe, Arlene

Agent Fisher Adams Kelly

Pub. Number AU-B-2006254902

PCT Pub. Number WO2006/133396

Priority 60/688,872 08.06.05 US

Filing date 8 June 2006

Wipo publication date 14 December 2006

Acceptance publication date 12 April 2012

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

24 January 2008 PCT application entered the National Phase

  PCT publication WO2006/133396 Priority application(s): WO2006/133396

12 April 2012 Application Accepted

  Published as AU-B-2006254902

9 August 2012 Standard Patent Sealed

16 August 2012 Corrigenda

  Applications Accepted - Name Index Under the name President and Fellows of Harvard College, Application No. 2006254902, under INID (72) correct the co-inventor to Freeman, Gordon Corrigenda

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006254917-Method of applying a design to a surface

2006254899-Treatment of sleep-wake disorders